3 completed, 3 terminated, 2 active not recruiting, 2 withdrawn. 6 Phase 2, 3 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow PT-100 dipeptide: new trials by email Literature Review of PT-100 dipeptide trials Research Report on PT-100 dipeptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma BXCL701, Pembrolizumab - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Active not recruiting | Georgetown University | 22 | 2023-08-16 | 2026-09-14 |
| BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome BXCL701 - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 1 | Active not recruiting | Eric Stephen Winer, MD | 12 | 2023-02-02 | 2026-10-19 |
| Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers Pembrolizumab, Talabostat Mesylate - Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 2 | Terminated | M.D. Anderson Cancer Center | 31 | 2020-03-19 | 2025-05-16 |
| A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Talabostat Mesylate - Cancer of Pancreas, Cancer of the Pancreas | Early Phase 1 | Withdrawn | BioXcel Therapeutics Inc | 2019-10-15 | 2026-08-11 | |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. BXCL701 plus Pembrolizumab, BXCL701 monotherapy - Prostate Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 98 | 2019-02-12 | 2026-05-15 |
| Talabostat in Treating Patients With Metastatic Kidney Cancer talabostat mesylate, enzyme inhibitor therapy, flow cytometry - Kidney Cancer | Phase 2 | Withdrawn | University of Nebraska | 2006-12-01 | 2023-08-22 | |
| Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy talabostat mesylate, docetaxel - Carcinoma, Non-Small Cell Lung | Phase 3 | Terminated | Point Therapeutics | 400 | 2006-01-01 | 2007-06-08 |
| Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors carboplatin, talabostat mesylate, temozolomide - Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 26 | 2005-12-01 | 2012-03-15 |
| Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) Talabostat mesylate (PT-100) tablets, Rituximab - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Point Therapeutics | 2015-03-25 | ||
| Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas talabostat mesylate tablets, gemcitabine - Pancreatic Cancer, Neoplasm Metastasis | Phase 2 | Terminated | Point Therapeutics | 60 | 2007-06-08 |
Kidney Neoplasms (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Astrocytoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Small Cell (1) · Central Nervous System Neoplasms (1) · Choroid Plexus Neoplasms (1) · Familial ependymoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Medulloblastoma (1)
Point Therapeutics (3) · BioXcel Therapeutics Inc (2) · Eric Stephen Winer, MD (1) · Georgetown University (1) · M.D. Anderson Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1) · University of Nebraska (1)
United States (9) · United Kingdom (1)
Amir Hafeez, MD (1) · Aung Naing, MD (1) · Benjamin Weinberg, MD (1) · BioXcel MM, MD (1) · Elizabeth Fox, MD (1) · Eric S Winter, MD (1) · Holly Meany, MD (1) · Ralph Hauke, MD (1) · Vincent O'Neill, MD (1)